Sam Schulman, Michelle Sholzberg, Alex C Spyropoulos, Ryan Zarychanski, Helaine E Resnick, Charlotte A Bradbury, Lisa Broxmeyer, Jean Marie Connors, Anna Falanga, Toshiaki Iba, Scott Kaatz, Jerrold H Levy, Saskia Middeldorp, Tracy Minichiello, Eduardo Ramacciotti, Charles Marc Samama, Jecko Thachil
Antithrombotic agents reduce risk of thromboembolism in severely ill patients. Patients with coronavirus disease 2019 (COVID-19) may realize additional benefits from heparins. Optimal dosing and timing of these treatments and benefits of other antithrombotic agents remain unclear. In October 2021, ISTH assembled an international panel of content experts, patient representatives, and a methodologist to develop recommendations on anticoagulants and antiplatelet agents for patients with COVID-19 in different clinical settings...
October 2022: Journal of Thrombosis and Haemostasis: JTH